Tempo Therapeutics, Inc.
San Diego, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3030 Bunker Hill St #308, San Diego, CA 92109, USA
- Website
- tempothera.com
- Founded
- 2014
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Gel4Med Inc. | Newton, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Bioaesthetics Corporation | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Insoma Bio, Inc. | Durham, NC | — |
| Epibone, Inc. | New York, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Tempo Therapeutics, Inc. is a biotechnology and tissue engineering company specializing in speeding up patient recovery. They have received multiple federal grants to support the development of regenerative medicine products, including a synthetic tissue scaffold to treat diabetic wounds and a novel vaccine platform.
Past federal grants awarded to Tempo Therapeutics, Inc. have supported the development and testing of the MAP Wound Matrix, a flowable synthetic tissue scaffold to regenerate tissue over exposed bone for complex wounds in diabetic patients. A $6.5 million project grant from the National Institutes of Health is funding a multi-center clinical trial of the MAP Wound Matrix. The company also received a $1.6 million NIH grant previously to develop the MAP technology for diabetic wounds. Additionally, Tempo Therapeutics has received federal grants from the National Science Foundation, including a $1 million cooperative agreement to develop a multivalent vaccine platform to provide durable immunity against multiple coronaviruses. This builds on an earlier NSF SBIR Phase I grant of $256,000 to develop a vaccine using their technology. The products and technologies Tempo Therapeutics is developing through these federal grants aim to meet significant unmet medical needs and have potential high commercial value.
Quick answers
Is Tempo Therapeutics, Inc. registered in SAM.gov?
Yes. Tempo Therapeutics, Inc.'s SAM.gov registration is active through August 26, 2027.
What is Tempo Therapeutics, Inc.'s CAGE code?
Tempo Therapeutics, Inc.'s CAGE code is 799L6, and its Unique Entity ID (UEI) is EA4HW67GFBS1.
What is Tempo Therapeutics, Inc.'s most recent federal award?
Tempo Therapeutics, Inc.'s most recent federal grant award is Sttr phase II: vaxmap a single dose multivalent vaccine to produce durable and cross-reactive immunity against… (2308751), from National Science Foundation, on June 15, 2023.
On GovTribe
See Tempo Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors